Jens H. Vogel
President & COO of Mirai Bio - Former CEO of BI Fremont & Global Head of Biotech at Bayer Pharmaceuticals
For the patients, we must do better.
Push boundaries, affect change
BILS 2026. The 18th Annual Bio Innovation Leaders Summit brings together c-suite, executives, pioneering thinkers and leading academics who are committed to breaking free from traditional silos to evolve and make an impact. Our curated programme is for leaders interested in strategy and innovation that will harness the full potential of the development of promising biologics and cell and gene therapies.
Agenda Framework
-
How can we leverage advanced technologies to reveal the significant value of innovative biologics and cell gene therapies?
-
Preparing Biopharma for the Biosecure Act
-
New frontier for CDMO's
-
Will personalised therapies and precision medicine leverage Al to deliver tailored treatments for complex diseases?
-
Building a sustainable tomorrow and fueling a bioeconomy for a resilient future future of biomanufacturing and global supply chain
-
Are we entering a new cell and gene therapy era with artificial intelligence?
-
Can we turn challenges into opportunities in the cultured meat industry?
-
Investor caution - valley of death between r&d and scaling
-
Talent shortages: how can we do better?
CURRENT SPEAKERS
AGENDA SCHEDULE
Biologics
-
Risk sharing partnerships CDMO
-
Advance manufacturing
-
Single use innovation
-
Digital Twins
-
Process intensification
-
Process validation
-
Biologic workflow solutions
-
Bioprocessing Training
-
Quality control and analysis
-
Predict clinical outcomes
-
Impact global suppychain
-
Modular CDMO - site selection
-
Safety and Efficiency
-
Automation, digitising, robotics
-
Process optimisation
-
Leverage Regulatory Pathways
-
Cell engineering & development
-
Scaling and commercialisation
-
Customer acceptance
-
Survival - Valley of Death
-
Regulatory frameworks
-
Continuous processing
-
Technologies roles in culinary innovation
-
Investor roadmap
-
Cultivated meat tasting
Joshi Venugopal
GM & Head of Europe
Novartis Gene Therapies & Rare Diseases
Dorothee Ambrosius
Former Head of CMC Strategy Biologicals
Boehringer Ingelheim
Warner Biddle
Former Global Head of Commercial
Kite, a Gilead Company
Gwendolyn Binder
President of Science & Technology
Cabaletta Bio
Pierre Caloz
COO
uniQure
Paolo Martini
Former CSO
Moderna
IN PERSON ONLY
Benchmark with up to only 200 leaders across Biopharma
SUMMIT
INSIGHTS
Our Mission
Our purpose is to create a gathering that empowers and inspires critical decision-making; sparking new opportunities to amplify their impact within the biologics and cell and gene therapy value chain.
We encourage collaboration and innovation, which is why this summit ensures that each participant contributes significantly to advancing the field. It serves as a platform for sharing insights, fostering partnerships and driving forward the next wave of breakthroughs in biologics.
For the patients, we must do better.
Investors and large biopharma companies need to satisfy environmental compliance. We will keynote the progression toward more sustainable bioprocesses, manufacturing and supply methods, amalgamating toward building a sustainable and digitised ecosystem - an emerging frontier of digitisation and industry 4.0.
Closing session by Merck.
Attendee Profile
C-Suite - Directors - Executives
Bioprocess - Manufacturing - IT-Data Integration - Commercial and Business Development - Scientists - Supply Chain - Production - PAT
Focus Area
CGT
Antibody Drugs
Vaccine
Small molecule, conjugates and peptides
Technology or Service Companies
CRO
CDMO
Biologic workflow solutions
Advance Bioprocessing
End to end workflow solutions
Digitising - AI - Data
Automation - Robotics
Filtration - Single use - Bioreactors
Event highlights
Pre Event Innovation Tour - Private Innovation Tour - CXO
Please click to Tour 2024
Evening of day one -Private Networking Dinner
Journey of a CXO
Exclusive closed-door talks from some of the most prominent leaders in the industry who will be talking about their journey, lessons learnt and vision for the future.
Attendance Guide
30% Asian Biopharma
25% International Biopharma
20% CMOs - CDMOS's
15% Academic & Research Institutes
10% Technology & Service Providers
Curated Meetings
Packages have sold out
Guaranteed pre-qualified strategy meetings
Prior contact
Mutual benefit
Conducted by our specialists
Geography
25% Korea & Japan
20% Singapore
20% Indonesia, Thailand, Philippines, Malaysia, India & Australia
15% China, Hong Kong & Taiwan
15% USA
5% UAE
PREVIOUS SPEAKERS
For the patients, we must do better
ADVISORY
“Our very survival depends on our ability to stay awake, to adjust to new ideas, to remain vigilant and to face the challenge of change” Martin Luther King
Subscribe to Our Mailing List
